Moderna's Intismeran Close to Keytruda Style Oncology Opportunity: Analyst - Moderna (NASDAQ:MRNA)

Moderna stock drops 12% after 177% surge: Here’s what Wall Street says about MRNA

Moderna-Merck Phase 3: intismeran (mRNA + Keytruda) improves recurrence-free survival in melanoma; stock surged 177%, fell 12% on profit-taking. Wall Street consensus: real value depends on cancer platform replicability across tumors and adoption, not melanoma opportunity.